Deciphex, a leader in AI-powered digital pathology, has raised $32.3 million in Series C funding, led by Molten Ventures with significant participation from ACT Venture Capital, Seroba, Charles River Laboratories, IRRUS Investments, HBAN Medtech Syndicate, and Nextsteps Capital. This investment will help Deciphex address the global pathology crisis by expanding access to high-quality diagnostics through a technology-driven network of pathologists.
With over 70% of healthcare decisions relying on pathology, Deciphex’s platforms, Diagnexia and Patholytix, use AI to boost pathologists' efficiency by up to 40%, reducing diagnostic delays and backlogs. Founded in 2017, Deciphex’s platforms streamline diagnostic workflows and support drug development by automating routine tasks, enabling pathologists to focus on complex cases.
The funding will support Deciphex’s global expansion to meet rising demand, enhance platforms, and develop AI models using a large image repository for better clinical and non-clinical applications. Strategic partnerships with Novartis and Charles River Laboratories will strengthen AI models for toxicology and preclinical safety evaluations.
Donal O’Shea, Founder and CEO, highlighted that the funding will help accelerate global access to AI-driven pathology, improving healthcare efficiency and supporting both pathologists and patients. Through its innovations and partnerships, Deciphex continues to transform global pathology services and advance healthcare delivery.
Click here to read the original news story.